Evidence map›Paper›PMID 38916527›Full record

ArticleACS chemical biology2024

De Novo Synthesis and Structural Elucidation of CDR-H3 Loop Mimics.

Guangkuan Zhao, Alexis D Richaud, R Thomas Williamson, Michael Feig, Stéphane P Roche

Abstract read
In one paragraph

Article in ACS chemical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guangkuan ZhaoDepartment of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, Florida 33431, United States.
Alexis D RichaudDepartment of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, Florida 33431, United States.
R Thomas WilliamsonDepartment of Chemistry and Biochemistry, University of North Carolina Wilmington, Wilmington, North Carolina 28409, United States.ORCID 0000-0001-7450-3135
Michael FeigDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, United States.ORCID 0000-0001-9380-6422
Stéphane P RocheDepartment of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, Florida 33431, United States.ORCID 0000-0002-3019-2168

Funding

Modeling and dynamics of biomolecules on cellular scalesR35GM126948 · NIGMS · MICHIGAN STATE UNIVERSITY · PI Michael Feig · 2018 to 2026
$3.2M
Flexible Rigidity in Peptide Drug Design for Protein-Protein Interaction InhibitorsR21GM132754 · NIGMS · FLORIDA ATLANTIC UNIVERSITY · PI ROCHE, STEPHANE P · 2019 to 2020
$401k
NIGMS NIH HHS R21 GM132754NIGMS NIH HHS R35 GM126948
6 · The paper itself

Abstract

The binding affinity of antibodies to specific antigens stems from a remarkably broad repertoire of hypervariable loops known as complementarity-determining regions (CDRs). While recognizing the pivotal role of the heavy-chain 3 CDRs (CDR-H3s) in maximizing antibody-antigen affinity and specificity, the key structural determinants responsible for their adaptability to diverse loop sequences, lengths, and noncanonical structures are hitherto unknown. To address this question, we achieved a de novo synthesis of bulged CDR-H3 mimics excised from their full antibody context. CD and NMR data revealed that these stable standalone β-hairpin scaffolds are well-folded and retain many of the native bulge CDR-H3 features in water. In particular, the tryptophan residue, highly conserved across CDR-H3 sequences, was found to extend the kinked base of these β-bulges through a combination of stabilizing intramolecular hydrogen bond and CH/π interaction. The structural ensemble consistent with our NMR observations exposed the dynamic nature of residues at the base of the loop, suggesting that β-bulges act as molecular hinges connecting the rigid stem to the more flexible loops of CDR-H3s. We anticipate that this deeper structural understanding of CDR-H3s will lay the foundation to inform the design of antibody drugs broadly and engineer novel CDR-H3 peptide scaffolds as therapeutics.

Indexed as

Complementarity Determining RegionsAmino Acid SequenceHumansImmunoglobulin Heavy ChainsModels, MolecularComplementarity Determining RegionsImmunoglobulin Heavy Chains

Identifiers

PMID38916527
PMCPMC11299430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.